Market Intelligence, Clinical Progress, and High-Purity Reagents for Obesity and Type 2 Diabetes Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IAPP (Amylin) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Human IAPP (1-37) Recombinant Peptide / Aggregation-Prone Mutants (S20G) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (for fusion constructs). |
View IAPP Products |
| Gene Delivery | IAPP Promise-ORF / Lentivirus Full-length ORF for stable cell lines; mutant variants available. Also: CALCR & RAMP1/2/3 Lentivirus for AMY receptor stable cell line construction (cAMP assays). |
View IAPP Products |
| Benchmark Ab | Anti-IAPP (Amylin) / Anti-Oligomer Antibodies Recombinant positive control; sequence-defined epitope mapping. |
View IAPP Products |
| Validator | IAPP siRNA Set For knockdown verification and specificity controls. |
View IAPP Products |
| Related Target: CALCR | Calcitonin Receptor (CTR) Core component of Amylin receptors (AMY1/2/3); required for functional assays. |
View CALCR Products |
| Related Target: RAMP1 | Receptor Activity Modifying Protein 1 Defines AMY1 receptor phenotype; co-expression with CALCR required. |
View RAMP1 Products |
| Related Target: RAMP3 | Receptor Activity Modifying Protein 3 Defines AMY3 receptor phenotype; critical for receptor selectivity studies. |
View RAMP3 Products |
| Related Target: GLP-1R | Glucagon-Like Peptide 1 Receptor Synergistic target for combination obesity therapies. |
View GLP-1R Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Amyloid Aggregation Kinetics & Toxicity Modeling | Monomeric and pre-aggregated IAPP preparations (>95% purity) with sequence-verified pathogenic mutants (S20G) for reliable oligomerization assays. |
| Receptor Selectivity (AMY1/2/3 vs CTR) | Individual CALCR and RAMP (1/2/3) proteins available for combinatorial reconstitution; enables precise subfamily selectivity screening. |
| Cross-species Translation (Cyno/Mouse/Rat) | Human/Mouse/Rat/Cyno IAPP orthologs with species-specific sequence verification and endotoxin control (<1 EU/µg) for preclinical safety pharmacology. |
| False Positives / Target Engagement | Validated siRNA and neutralizing antibody controls included for specificity verification in cellular aggregation toxicity assays. |
| Receptor Complex Conformation | Lentivirus-mediated stable co-expression of CALCR and RAMPs for native GPCR environment. |
| Lack of Controls for PK Assays | High-affinity Anti-Amylin antibodies provided for reliable pharmacokinetic sandwich ELISAs. |
Live IAPP (Amylin) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation Amylin therapeutics is intensifying, with major players shifting focus from simple peptide replacements to sophisticated multi-agonist modalities. Following the clinical validation of Pramlintide, the field is pivoting toward long-acting Amylin analogs and dual/triple agonists (Amylin/GLP-1/Glucagon) for obesity and Type 2 Diabetes. As first-generation combination therapies reach Phase III, the next wave of R&D is targeting aggregation-resistant scaffolds and receptor-subtype selective agonists to minimize calcitonin-related off-target effects while preserving β-cell protective benefits. Amylin analogues demonstrate unique mechanisms for satiety and potentially offer superior lean mass preservation compared to standard GLP-1 receptor agonists, making them a cornerstone for the next generation of obesity management. Key players include Novo Nordisk (Cagrilintide, CagriSema), Zealand Pharma (Petrelintide), AstraZeneca (AZD6234), and Eli Lilly.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-Acting Peptide Analogs | Novo Nordisk (Cagrilintide), AstraZeneca, Zealand Pharma | Obesity, T2D | Aggregation Resistance Assay (Need high-purity monomeric IAPP and S20G mutant controls); Receptor Activation Assay (Need CALCR/RAMP Lentivirus for Stable Cells) |
| Multi-agonist (Amylin/GLP-1) | Novo Nordisk (CagriSema), Eli Lilly | Refractory Obesity | Receptor Selectivity Panel (Need CALCR + RAMP1/2/3 combinatorial proteins); Cross-Reactivity & Synergy (Need High-Purity GLP-1R & CALCR expressing cells) |
| Aggregation Inhibitors (Small Molecule/Ab) | Academic/Preclinical Biotech | T2D (β-cell protection) | Toxic Oligomer Binding Assay (Need conformation-specific anti-IAPP antibodies) |
| Gene Therapy | Early Stage Startups | Monogenic Diabetes | Expression Validation (Need IAPP-specific antibodies and qPCR standards) |
| Small Molecule Agonist | Various Biotechs | Metabolic Syndrome | Selectivity Assay (Need Sequence Verified Receptor Subtypes) |